Meeting the Costs of HIV Care

The Latest

Government Panel Finds PrEP Is Effective, Must Be Available Free of Cost to Patients

The US Preventive Services Task Force released its final ruling in JAMA.

By Kenyon Farrow

Ending the HIV Epidemic Will Take More Than Medicine

Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.

By Stephaun E. Wallace, Ph.D.

Advances in HIV Science Must Not Leave Needs of People Behind, Experts Urge

As the 2019 National HIV Prevention Conference kicked off on March 18, plenary speakers discussed not only recent biomedical advances, but also what is truly needed in heavily affected U.S. communities to end the epidemic.

By Sony Salzman

Staying on PrEP is Significantly Different for PrEP Users With Commercial Insurance Versus Medicaid

Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.

By Stephen Hicks

Pharma Payments to Doctors Associated With Spike in Opioid Deaths, New Study Reveals

After years of anecdotes and speculation, harm reduction and pharma watchdog advocates have data to back claims that the spike in opioid deaths in the U.S. can be tied to pharmaceutical companies marketing highly addictive opioids to doctors.

By Kenyon Farrow

This Week in HIV Research: Do We Need New Statin Guidelines?

Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Case for Pre-Pregnancy Treatment

The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.

By Barbara Jungwirth and Myles Helfand

California: A Health Care Laboratory With Mixed Results

A report on HIV patients is one example showing that though the state is often a national beacon in health care, some of its innovations fall short of expectations.

By Anna Gorman for Henry J. Kaiser Family Foundation

With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing

The Initiative for Medicines, Access and Knowledge, Inc. (I-MAK) argues that the high price of hepatitis C cure medicines places them out of reach for most people.

By Sony Salzman

This Week in HIV Research: Erectile Dysfunction in the Modern Age

Reductions in erectile function among men who have sex with men; Australia, San Francisco, and 90-90-90 “fast track” targets; hepatitis C infection and HIV risk; safety of the live herpes zoster vaccine.

By Barbara Jungwirth and Myles Helfand